

Junnian Zheng

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4212664/publications.pdf>

Version: 2024-02-01

135
papers

4,592
citations

172386

29
h-index

138417

58
g-index

142
all docs

142
docs citations

142
times ranked

6377
citing authors

#	ARTICLE	IF	CITATIONS
1	Turning Cold into Hot: Firing up the Tumor Microenvironment. <i>Trends in Cancer</i> , 2020, 6, 605-618.	3.8	562
2	Translation and functional roles of circular RNAs in human cancer. <i>Molecular Cancer</i> , 2020, 19, 30.	7.9	422
3	A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2019, 6, e521-e529.	2.2	211
4	DNA damage response – A double-edged sword in cancer prevention and cancer therapy. <i>Cancer Letters</i> , 2015, 358, 8-16.	3.2	155
5	Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2018, 93, 851-858.	2.0	138
6	Decorin is a pivotal effector in the extracellular matrix and tumour microenvironment. <i>Oncotarget</i> , 2018, 9, 5480-5491.	0.8	118
7	LINC00460/DHX9/IGF2BP2 complex promotes colorectal cancer proliferation and metastasis by mediating HMGA1 mRNA stability depending on m6A modification. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 52.	3.5	112
8	Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models. <i>Journal of Immunology Research</i> , 2018, 2018, 1-11.	0.9	92
9	The emerging role of RUNX3 in cancer metastasis (Review). <i>Oncology Reports</i> , 2016, 35, 1227-1236.	1.2	91
10	Methylation of EZH2 by PRMT1 regulates its stability and promotes breast cancer metastasis. <i>Cell Death and Differentiation</i> , 2020, 27, 3226-3242.	5.0	87
11	p53-mediated autophagic regulation: A prospective strategy for cancer therapy. <i>Cancer Letters</i> , 2015, 363, 101-107.	3.2	83
12	PTBP3-Mediated Regulation of ZEB1 mRNA Stability Promotes Epithelial-Mesenchymal Transition in Breast Cancer. <i>Cancer Research</i> , 2018, 78, 387-398.	0.4	75
13	DCAF1 regulates Treg senescence via the ROS axis during immunological aging. <i>Journal of Clinical Investigation</i> , 2020, 130, 5893-5908.	3.9	71
14	Rap2B promotes proliferation, migration and invasion of human breast cancer through calcium-related ERK1/2 signaling pathway. <i>Scientific Reports</i> , 2015, 5, 12363.	1.6	70
15	Causal association of type 2 diabetes with amyotrophic lateral sclerosis: new evidence from Mendelian randomization using GWAS summary statistics. <i>BMC Medicine</i> , 2019, 17, 225.	2.3	63
16	Synergistic Effects of Cabozantinib and EGFR-Specific CAR-NK-92 Cells in Renal Cell Carcinoma. <i>Journal of Immunology Research</i> , 2017, 2017, 1-14.	0.9	62
17	PinX1 inhibits the invasion and metastasis of human breast cancer via suppressing NF- κ B/MMP-9 signaling pathway. <i>Molecular Cancer</i> , 2015, 14, 66.	7.9	53
18	CAIX-specific CAR-T Cells and Sunitinib Show Synergistic Effects Against Metastatic Renal Cancer Models. <i>Journal of Immunotherapy</i> , 2020, 43, 16-28.	1.2	53

#	ARTICLE	IF	CITATIONS
19	Positive feedback loop between cancer stem cells and angiogenesis in hepatocellular carcinoma. <i>Cancer Letters</i> , 2016, 379, 213-219.	3.2	52
20	Coagulation Disorders after Chimeric Antigen Receptor T Cell Therapy: Analysis of 100 Patients with Relapsed and Refractory Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 865-875.	2.0	51
21	iRGD as a tumor-penetrating peptide for cancer therapy. <i>Molecular Medicine Reports</i> , 2017, 15, 2925-2930.	1.1	49
22	A chimeric antigen receptor with antigen-independent OX40 signaling mediates potent antitumor activity. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	49
23	Post-translational modifications of EZH2 in cancer. <i>Cell and Bioscience</i> , 2020, 10, 143.	2.1	47
24	Expanding uncapped translation and emerging function of circular RNA in carcinomas and noncarcinomas. <i>Molecular Cancer</i> , 2022, 21, 13.	7.9	43
25	Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2022, 40, 2246-2256.	0.8	43
26	Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment. <i>Frontiers in Immunology</i> , 2021, 12, 611366.	2.2	41
27	AIM2 is a potential therapeutic target in human renal carcinoma and suppresses its invasion and metastasis via enhancing autophagy induction. <i>Experimental Cell Research</i> , 2018, 370, 561-570.	1.2	38
28	Trim21-mediated HIF-1 α degradation attenuates aerobic glycolysis to inhibit renal cancer tumorigenesis and metastasis. <i>Cancer Letters</i> , 2021, 508, 115-126.	3.2	37
29	Phase II trial of coadministration of CD19 α and CD20 α -targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma. <i>Cancer Medicine</i> , 2020, 9, 5827-5838.	1.3	36
30	Role of RUNX3 in Suppressing Metastasis and Angiogenesis of Human Prostate Cancer. <i>PLoS ONE</i> , 2014, 9, e86917.	1.1	35
31	The development of CAR design for tumor CAR-T cell therapy. <i>Oncotarget</i> , 2018, 9, 13991-14004.	0.8	31
32	Blockade of AIM2 inflammasome or β 1-AR ameliorates IL-1 β release and macrophage-mediated immunosuppression induced by CAR-T treatment. , 2021, 9, e001466.		31
33	PRMT1-mediated EZH2 methylation promotes breast cancer cell proliferation and tumorigenesis. <i>Cell Death and Disease</i> , 2021, 12, 1080.	2.7	31
34	Discoidin domain receptor 1 (DDR1), a promising biomarker, induces epithelial to mesenchymal transition in renal cancer cells. <i>Tumor Biology</i> , 2016, 37, 11509-11521.	0.8	30
35	Selective pericellular hydrogelation by the overexpression of an enzyme and a membrane receptor. <i>Nanoscale</i> , 2019, 11, 13714-13719.	2.8	30
36	PTBP3 contributes to colorectal cancer growth and metastasis via translational activation of HIF-1 α . <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 301.	3.5	30

#	ARTICLE	IF	CITATIONS
37	PinX1 represses renal cancer angiogenesis via the mir-125a-3p/VEGF signaling pathway. <i>Angiogenesis</i> , 2019, 22, 507-519.	3.7	30
38	DNA methylome profiling of circulating tumor cells in lung cancer at single base-pair resolution. <i>Oncogene</i> , 2021, 40, 1884-1895.	2.6	27
39	Rap2B promotes cell proliferation, migration and invasion in prostate cancer. <i>Medical Oncology</i> , 2016, 33, 58.	1.2	26
40	A Novel Strategy to Improve the Therapeutic Efficacy of Gemcitabine for Non-Small Cell Lung Cancer by the Tumor-Penetrating Peptide iRGD. <i>PLoS ONE</i> , 2015, 10, e0129865.	1.1	26
41	Rap2B promotes angiogenesis via PI3K/AKT/VEGF signaling pathway in human renal cell carcinoma. <i>Tumor Biology</i> , 2017, 39, 101042831770165.	0.8	25
42	A prognosis and impact factor analysis of DC-CIK cell therapy for patients with hepatocellular carcinoma undergoing postoperative TACE. <i>Cancer Biology and Therapy</i> , 2018, 19, 475-483.	1.5	25
43	Inhibition of Cdk8/Cdk19 Activity Promotes Treg Cell Differentiation and Suppresses Autoimmune Diseases. <i>Frontiers in Immunology</i> , 2019, 10, 1988.	2.2	25
44	CRISPR screen in mechanism and target discovery for cancer immunotherapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1874, 188378.	3.3	25
45	Preoperative neutrophil-to-lymphocyte ratio is a more valuable prognostic factor than platelet-to-lymphocyte ratio for nonmetastatic rectal cancer. <i>International Immunopharmacology</i> , 2016, 40, 327-331.	1.7	24
46	HCRP-1 regulates EGFR- AKT -BIM-mediated anoikis resistance and serves as a prognostic marker in human colon cancer. <i>Cell Death and Disease</i> , 2018, 9, 1176.	2.7	24
47	Combining DNA Vaccine and AIM2 in H1 Nanoparticles Exert Anti-Renal Carcinoma Effects via Enhancing Tumor-Specific Multi-functional CD8 ⁺ T-cell Responses. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 323-334.	1.9	24
48	The nuclear translocation of transketolase inhibits the farnesoid receptor expression by promoting the binding of HDAC3 to FXR promoter in hepatocellular carcinoma cell lines. <i>Cell Death and Disease</i> , 2020, 11, 31.	2.7	24
49	BRMS1 Suppresses Glioma Progression by Regulating Invasion, Migration and Adhesion of Glioma Cells. <i>PLoS ONE</i> , 2014, 9, e98544.	1.1	24
50	RUNX3 regulates renal cell carcinoma metastasis via targeting miR-6780a-5p/E-cadherin/EMT signaling axis. <i>Oncotarget</i> , 2017, 8, 101042-101056.	0.8	24
51	HCRP-1 regulates cell migration and invasion via EGFR-ERK mediated up-regulation of MMP-2 with prognostic significance in human renal cell carcinoma. <i>Scientific Reports</i> , 2015, 5, 13470.	1.6	23
52	Discoidin domain receptor 1: New star in cancer-targeted therapy and its complex role in breast carcinoma (Review). <i>Oncology Letters</i> , 2018, 15, 3403-3408.	0.8	23
53	The role of Aurora-A in cancer stem cells. <i>International Journal of Biochemistry and Cell Biology</i> , 2018, 98, 89-92.	1.2	23
54	MDMX Recruits UbcH5c to Facilitate MDM2 E3 Ligase Activity and Subsequent p53 Degradation <i>In Vivo</i> . <i>Cancer Research</i> , 2021, 81, 898-909.	0.4	22

#	ARTICLE	IF	CITATIONS
55	ING4 suppresses tumor angiogenesis and functions as a prognostic marker in human colorectal cancer. <i>Oncotarget</i> , 2016, 7, 79017-79031.	0.8	21
56	Estrogen potentiates reactive oxygen species (ROS) tolerance to initiate carcinogenesis and promote cancer malignant transformation. <i>Tumor Biology</i> , 2016, 37, 141-150.	0.8	21
57	Chimeric antigen receptor-T cell therapy for solid tumors require new clinical regimens. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 1099-1106.	1.1	21
58	Nifuroxazide prompts antitumor immune response of TCL-loaded DC in mice with orthotopically-implanted hepatocarcinoma. <i>Oncology Reports</i> , 2017, 37, 3405-3414.	1.2	21
59	Overexpression of HDAC6 suppresses tumor cell proliferation and metastasis by inhibition of the canonical Wnt/ β -catenin signaling pathway in hepatocellular carcinoma. <i>Oncology Letters</i> , 2018, 16, 7082-7090.	0.8	21
60	Safety and efficacy of chimeric antigen receptor (CAR)-T-cell therapy in persons with advanced B-cell cancers and hepatitis B virus-infection. <i>Leukemia</i> , 2020, 34, 2704-2707.	3.3	21
61	Transketolase promotes colorectal cancer metastasis through regulating AKT phosphorylation. <i>Cell Death and Disease</i> , 2022, 13, 99.	2.7	21
62	Peglated-H1/pHGFK1 nanoparticles enhance anti-tumor effects of sorafenib by inhibition of drug-induced autophagy and stemness in renal cell carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 362.	3.5	20
63	Macrophages-stimulated PRMT1-mediated EZH2 methylation promotes breast cancer metastasis. <i>Biochemical and Biophysical Research Communications</i> , 2020, 533, 679-684.	1.0	19
64	Efficacy of an Oncolytic Adenovirus Driven by a Chimeric Promoter and Armed with Decorin Against Renal Cell Carcinoma. <i>Human Gene Therapy</i> , 2020, 31, 651-663.	1.4	19
65	Tumor-penetration and antitumor efficacy of cetuximab are enhanced by co-administered iRGD in a murine model of human NSCLC. <i>Oncology Letters</i> , 2016, 12, 3241-3249.	0.8	18
66	Chimeric antigen receptor-modified T Cells inhibit the growth and metastases of established tissue factor-positive tumors in NOG mice. <i>Oncotarget</i> , 2017, 8, 9488-9499.	0.8	18
67	Cleavage and phosphorylation: important post-translational modifications of galectin-3. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 367-374.	2.7	17
68	H1/pHGFK1 nanoparticles exert anti-tumoural and radiosensitising effects by inhibition of MET in glioblastoma. <i>British Journal of Cancer</i> , 2018, 118, 522-533.	2.9	17
69	DKC1 serves as a potential prognostic biomarker for human clear cell renal cell carcinoma and promotes its proliferation, migration and invasion via the NF κ B pathway. <i>Oncology Reports</i> , 2018, 40, 968-978.	1.2	17
70	H1/pAIM2 nanoparticles exert anti-tumour effects that is associated with the inflammasome activation in renal carcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 5670-5681.	1.6	17
71	Targeted Hsp70 expression combined with CIK-activated immune reconstruction synergistically exerts antitumor efficacy in patient-derived hepatocellular carcinoma xenograft mouse models. <i>Oncotarget</i> , 2015, 6, 1079-1089.	0.8	17
72	Modification of IL-24 by tumor penetrating peptide iRGD enhanced its antitumor efficacy against non-small cell lung cancer. <i>International Immunopharmacology</i> , 2019, 70, 125-134.	1.7	16

#	ARTICLE	IF	CITATIONS
73	CD36 regulates LPS-induced acute lung injury by promoting macrophages M1 polarization. <i>Cellular Immunology</i> , 2022, 372, 104475.	1.4	16
74	RAS P21 Protein Activator 3 (RASA3) Specifically Promotes Pathogenic T Helper 17 Cell Generation by Repressing T-Helper-2-Cell-Biased Programs. <i>Immunity</i> , 2018, 49, 886-898.e5.	6.6	15
75	The Emerging Roles of RASSF5 in Human Malignancy. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2018, 18, 314-322.	0.9	15
76	High FOXK1 expression correlates with poor outcomes in hepatocellular carcinoma and regulates stemness of hepatocellular carcinoma cells. <i>Life Sciences</i> , 2019, 228, 128-134.	2.0	15
77	Birth Weight and Stroke in Adult Life: Genetic Correlation and Causal Inference With Genome-Wide Association Data Sets. <i>Frontiers in Neuroscience</i> , 2020, 14, 479.	1.4	15
78	An Analysis of Cardiac Disorders Associated With Chimeric Antigen Receptor T Cell Therapy in 126 Patients: A Single-Centre Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 691064.	1.3	15
79	Lenvatinib enhances T cell immunity and the efficacy of adoptive chimeric antigen receptor-modified T cells by decreasing myeloid-derived suppressor cells in cancer. <i>Pharmacological Research</i> , 2021, 174, 105829.	3.1	15
80	Antitumor activities of an oncolytic adenovirus equipped with a double siRNA targeting Ki67 and hTERT in renal cancer cells. <i>Virus Research</i> , 2014, 181, 61-71.	1.1	14
81	SPAG9 expression is increased in human prostate cancer and promotes cell motility, invasion and angiogenesis in vitro. <i>Oncology Reports</i> , 2014, 32, 2533-2540.	1.2	14
82	Structure, functional regulation and signaling properties of Rap2B. <i>Oncology Letters</i> , 2016, 11, 2339-2346.	0.8	14
83	Overexpression of CIP2A is associated with poor prognosis in multiple myeloma. <i>Signal Transduction and Targeted Therapy</i> , 2017, 2, 17013.	7.1	14
84	Kinetics of immune reconstitution after anti-CD19 chimeric antigen receptor T cell therapy in relapsed or refractory acute lymphoblastic leukemia patients. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 250-258.	0.7	14
85	Protein phosphatase PHLPP induces cell apoptosis and exerts anticancer activity by inhibiting Survivin phosphorylation and nuclear export in gallbladder cancer. <i>Oncotarget</i> , 2015, 6, 19148-19162.	0.8	14
86	Oncolytic adenovirus-mediated expression of decorin facilitates CAIX-targeting CAR-T therapy against renal cell carcinoma. <i>Molecular Therapy - Oncolytics</i> , 2022, 24, 14-25.	2.0	14
87	iNKT: A new avenue for CAR-based cancer immunotherapy. <i>Translational Oncology</i> , 2022, 17, 101342.	1.7	14
88	Humanized CD19-specific chimeric antigen-receptor T-cells in 2 adults with newly diagnosed B-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2019, 33, 2751-2753.	3.3	12
89	Humanized CD19-targeted chimeric antigen receptor T (CAR-T) cells for relapsed/refractory pediatric acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2021, 96, E162-E165.	2.0	12
90	Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy. <i>Frontiers in Immunology</i> , 2021, 12, 755549.	2.2	12

#	ARTICLE	IF	CITATIONS
91	Predictive role of endothelial cell activation in cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukaemia. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 11063-11074.	1.6	12
92	Disturbance of Mammary UDP-Glucuronosyltransferase Represses Estrogen Metabolism and Exacerbates Experimental Breast Cancer. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 2152-2162.	1.6	11
93	Inactivation of the MDM2 RING domain enhances p53 transcriptional activity in mice. <i>Journal of Biological Chemistry</i> , 2017, 292, 21614-21622.	1.6	11
94	Bortezomib improves adoptive carbonic anhydrase α -specific chimeric antigen receptor α -modified NK92 cell therapy in mouse models of human renal cell carcinoma. <i>Oncology Reports</i> , 2018, 40, 3714-3724.	1.2	11
95	ISG12a and its interaction partner NR4A1 are involved in TRAIL α -induced apoptosis in hepatoma cells. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 3520-3529.	1.6	11
96	TRAIL α activation promotes cleavage and nuclear translocation of Her2 and metastatic potential of cancer cells. <i>Cancer Science</i> , 2020, 111, 4417-4428.	1.7	11
97	The SKI proto-oncogene restrains the resident CD103 $^+$ CD8 $^+$ T cell response in viral clearance. <i>Cellular and Molecular Immunology</i> , 2020, 18, 2410-2421.	4.8	11
98	The molecular mechanism of acute liver injury and inflammatory response induced by Concanavalin A. <i>Molecular Biomedicine</i> , 2021, 2, 24.	1.7	11
99	Tumor-Penetrating Peptide Enhances Antitumor Effects of IL-24 Against Prostate Cancer. <i>Translational Oncology</i> , 2019, 12, 453-461.	1.7	10
100	Absent in melanoma 2-mediating M1 macrophages facilitate tumor rejection in renal carcinoma. <i>Translational Oncology</i> , 2021, 14, 101018.	1.7	9
101	C1QBP regulates T cells mitochondrial fitness to affect their survival, proliferation and anti-tumor immune function. <i>Cancer Science</i> , 2022, , .	1.7	9
102	Inhibition of mammalian target of rapamycin by rapamycin increases the radiosensitivity of esophageal carcinoma Eca109 cells. <i>Oncology Letters</i> , 2014, 8, 575-581.	0.8	8
103	Rap2B GTPase: structure, functions, and regulation. <i>Tumor Biology</i> , 2016, 37, 7085-7093.	0.8	8
104	JNK1/2 and ERK1/2 provides vital clues about tumor recurrence and survival in hepatocellular carcinoma patients. <i>Future Oncology</i> , 2018, 14, 2471-2481.	1.1	8
105	Rap2B promotes cell adhesion, proliferation, migration and invasion of human glioma. <i>Journal of Neuro-Oncology</i> , 2019, 143, 221-229.	1.4	8
106	Neural regulation of drug resistance in cancer treatment. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1871, 20-28.	3.3	8
107	HCRP-1 regulates cell migration, invasion and angiogenesis via Src/ FAK signaling in human prostate cancer. <i>International Journal of Biological Sciences</i> , 2020, 16, 342-352.	2.6	8
108	Tyrosine Kinase Inhibitor Cabozantinib Inhibits Murine Renal Cancer by Activating Innate and Adaptive Immunity. <i>Frontiers in Oncology</i> , 2021, 11, 663517.	1.3	8

#	ARTICLE	IF	CITATIONS
109	Co-immunization with Myc enhances CD8 ⁺ or CD103 ⁺ DCs mediated tumor-specific multi-functional CD8 ⁺ T cell responses. <i>Cancer Science</i> , 2021, 112, 3469-3483.	1.7	8
110	p53 upregulates PLC μ -IP3-Ca ²⁺ pathway and inhibits autophagy through its target gene Rap2B. <i>Oncotarget</i> , 2017, 8, 64657-64669.	0.8	8
111	The Pleiotropic Effects of miRNAs on Tumor Angiogenesis. <i>Journal of Cellular Biochemistry</i> , 2015, 116, 1807-1815.	1.2	7
112	Selective effects of a fiber chimeric conditionally replicative adenovirus armed with hep27 gene on renal cancer cell. <i>Cancer Biology and Therapy</i> , 2016, 17, 664-673.	1.5	7
113	MBD2 Correlates with a Poor Prognosis and Tumor Progression in Renal Cell Carcinoma. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 10001-10012.	1.0	7
114	A p53/CPEB2 negative feedback loop regulates renal cancer cell proliferation and migration. <i>Journal of Genetics and Genomics</i> , 2021, 48, 606-617.	1.7	7
115	Combination of Anti-CD19 and Anti-CD20 Chimeric Antigen Receptor T Cells for Relapsed and Refractory Diffuse Large B Cell Lymphoma: An Open-Label, Single-Arm, Phase I Trial. <i>Blood</i> , 2019, 134, 1590-1590.	0.6	7
116	Neutrophil Extracellular Traps in Digestive Cancers: Warrior or Accomplice. <i>Frontiers in Oncology</i> , 2021, 11, 766636.	1.3	7
117	Correlation of Cytokine Release Syndrome With Prognosis After Chimeric Antigen Receptor T Cell Therapy: Analysis of 54 Patients With Relapsed or Refractory Multiple Myeloma. <i>Frontiers in Immunology</i> , 2022, 13, 814548.	2.2	7
118	Downregulation of Frizzled-7 induces the apoptosis of hepatocellular carcinoma cells through inhibition of NF- κ B. <i>Oncology Letters</i> , 2018, 15, 7693-7701.	0.8	6
119	Manipulation of Mitochondrial Plasticity Changes the Metabolic Competition Between Foe and Friend During Tumor Malignant Transformation. <i>Frontiers in Oncology</i> , 2020, 10, 1692.	1.3	6
120	The optimization system for preparation of TG1 competent cells and electrotransformation. <i>MicrobiologyOpen</i> , 2020, 9, e1043.	1.2	6
121	Prevalence and factors associated with anxiety and depressive symptoms among patients hospitalized with hematological malignancies after chimeric antigen receptor T-cell (CAR-T) therapy: A cross-sectional study. <i>Journal of Affective Disorders</i> , 2021, 286, 33-39.	2.0	6
122	Dual-targeting vaccine of FGL1/CAIX exhibits potent anti-tumor activity by activating DC-mediated multi-functional CD8 T cell immunity. <i>Molecular Therapy - Oncolytics</i> , 2022, 24, 1-13.	2.0	6
123	Adenovirus vaccine therapy with CD137L promotes CD8 ⁺ DCs-mediated multifunctional CD8 ⁺ T cell immunity and elicits potent anti-tumor activity. <i>Pharmacological Research</i> , 2022, 175, 106034.	3.1	6
124	A p53-independent apoptotic mechanism of adenoviral mutant E1A was involved in its selective antitumor activity for human cancer. <i>Oncotarget</i> , 2016, 7, 48309-48320.	0.8	5
125	Role of Rap2 and its Downstream Effectors in Tumorigenesis. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2015, 15, 1269-1276.	0.9	5
126	Absent in melanoma 2 enhances anti-tumour effects of CAIX promoter controlled conditionally replicative adenovirus in renal cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 10744-10755.	1.6	4

#	ARTICLE	IF	CITATIONS
127	Efficacy and Safety of Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Immunoglobulin D Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 273.e1-273.e5.	0.6	4
128	Humanized CD19-Specific Chimeric Antigen Receptor T Cells for Acute Lymphoblastic Leukemia. <i>Blood</i> , 2019, 134, 3872-3872.	0.6	4
129	Absolute Lymphocyte Count Prior to Lymphodepletion Impacts Outcomes in Multiple Myeloma Patients Treated with Chimeric Antigen Receptor T Cells. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 118.e1-118.e5.	0.6	4
130	Simultaneous silencing Aurora-A and UHRF1 inhibits colorectal cancer cell growth through regulating expression of DNMT1 and STAT1. <i>International Journal of Medical Sciences</i> , 2021, 18, 3437-3451.	1.1	3
131	Safety and efficacy of a humanized <scp>CD19</scp> chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2022, 97, 711-718.	2.0	3
132	A novel role mediated by adenoviral E1A in suppressing cancer through modulating decorin. <i>Medical Oncology</i> , 2019, 36, 96.	1.2	2
133	Combination of oncolytic adenovirus targeting SATB1 and docetaxel for the treatment of castration-resistant prostate cancer. <i>Journal of Cancer</i> , 2021, 12, 1846-1852.	1.2	2
134	Co-immunizing with HMGB1 enhances anti-tumor immunity of B7H3 vaccine in renal carcinoma. <i>Molecular Immunology</i> , 2021, 139, 184-192.	1.0	2
135	Vitamin C through upregulating SYNPO2 level suppresses the proliferation and migration of glioma cells. <i>Jbuon</i> , 2021, 26, .	0.3	0